EASL DeepDive: Glucagon in MASH: A next step in “metabolic” drugs tackling liver disease?

In this EASL DeepDive held on 30 October 2024, Henning Grønbæk, Cyrielle Caussy, Mazen Noureddin and Frank Tacke provide an understanding of the role of glucagon and glucagon-receptors in physiology and in MASH patients. Additionally, they review key clinical trials and evaluate the integration of GLP-1 receptor agonists into current EASL-EASD-EASO clinical guidelines for practical patient management.

Learning objectives:

1. Understand the role of glucagon and glucagon-receptor in normal physiology and disease.
2. Understand the rationale of a combined dual GLP-1/GCG RA and its potential benefit compared to a GLP-1RA alone and thus gain insights into the mechanisms through which GLP-1 receptor agonists and GLP-1/GCG might affect liver pathology and metabolic regulation.
3. Discuss and review key clinical trials and ongoing development programs.
4. Evaluate how GLP-1RA can be integrated into current EASL-EASD-EASO CPGs, with a focus on practical applications and patient management strategies, giving potential guidance for future applications.

This EASL DeepDive webinar is supported by Boehringer Ingelheim. Boehringer Ingelheim has had no input into the content of this EASL DeepDive.